A. Glargine and albiglutide, detemir and liratglutide B. Degludec and dulaglutide, glargine and liraglutide C. Glargine and lixisenatide, degludec and liraglutide D. Degludec and exenatide and glargine and exenatide

A. First meal B. Second meal C. Third meal D. It does not matter what time you take your dose of Soliqua 100/33

A. Increase metformin ER to 2,000mg once daily and increase U100 glargine to 50units daily B. Increase metformin ER to 2,000mg once daily, discontinue U100 glargine and switch to U300 glargine 36units daily C. Continue metformin ER 1,500mg once daily, discontinue U100 glargine, and add Soliqua 100/33 starting at 15units daily D. Increase metformin ER to 2,000mg once daily, discontinue U100 glargine, and add Soliqua 100/33 starting at 30units daily

A. The maximum dose of Xultophy 100/3.6 is 50 units. B. Xultophy 100/3.6 should be titrated by 2-4 units weekly. C. Soliqua 100/33 can be given once a day at any time of the day regardless of food D. Oral contraceptives should be given 1 hour before or 11 hours after Xultophy 100/3.6 is injected.

A. Both products should be stored in the refrigerator once opened B. Both products should be stored at room temperature once opened C. Both products expire after 14days once opened D. Both products expire after 21 days once opened

A. Although this combination is not as good at basal-bolus insulin therapy for glycemic control, it results in less injections weekly (7 vs 21) and better adherence. B. The combination therapy has similar hypoglycemic risk as basal bolus insulin therapy. C. The combination therapy has more GI side effects than basal bolus insulin therapy. D. The combination therapy has similar weight gain to basal bolus insulin therapy.

A. A patient with an A1C no more than 2% higher than goal B. A patient who is uncontrolled on oral medications (no injectables) C. A patient with Type 1 or Type 2 diabetes if their A1C is within 1-1.5% of goal D. A patient who is at fasting blood sugar goal with a basal insulin but not at goal post meals.